The Filing Desk

NewAmsterdam Pharma vs Sol-Gel Technologies

NewAmsterdam Pharma NAMS · Sol-Gel Technologies SLGL · Pharmaceuticals

NewAmsterdam Pharma reported revenue of $22 million in fiscal 2025, 1.2 times Sol-Gel Technologies' $19 million in fiscal 2025. NewAmsterdam Pharma's revenue fell 50.6% in its latest year, and Sol-Gel Technologies' grew 68.0%. NewAmsterdam Pharma had an operating margin of -1002.9%, against -38.9% at Sol-Gel Technologies. Free cash flow was −$148 million at NewAmsterdam Pharma and $0 million at Sol-Gel Technologies.

Side by side

NewAmsterdam PharmaSol-Gel Technologies
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$22M$19M
Revenue growth−50.6%68.0%
Revenue growth a year, last 5 years—17.1%
Gross margin——
Operating margin−1,002.9%−38.9%
Net margin−905.7%−31.6%
Free cash flow−$148M$0M
Free cash flow margin−657.8%1.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count25.5%0.0%
Last close$19.51$54.08
P/E at the last close——
Insider trades, last 12 monthsbought $226,500, sold $62.0 millionbought $11.2 million, sold $0
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NewAmsterdam PharmaSol-Gel Technologies
Operating margin
Percent of revenue
NewAmsterdam PharmaSol-Gel Technologies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NewAmsterdam PharmaSol-Gel Technologies

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NewAmsterdam Pharma and Sol-Gel Technologies pages.